A sad litany of new examples suggests the FDA has lost its ability to reason about risk.
One way or another, investment managers are always accountable to their clients.
A U.S. initiative encourages businesses to see Africa’s poor as an untapped market.
Weight has always been hard to control, says a leading science writer.
Unless the public intervenes, a new rule will make patients sicker.
How the U.S. uses trade agreements to promote democracy
Making it cheaper to drive a mile won’t help the environment.
Nearly two years later, how goes the fight for eminent domain reform?
Paris Hilton, electronic spam, political loyalties and more...
Yesterday’s theatrics over stem cell funding overshadowed the real news: Scientists are finding ethical, alternative ways to get the same work done.
Last year’s ban on internet gambling marked a major setback for the industry, but Congress is taking a second look at the issue… and things might be changing in any case.
230 years later, the Marquis de Lafayette’s declaration of friendship for the United States still rings true.
The Stoneridge case could make nearly anyone liable for securities fraud at public companies.
Member states should insist on efficiency before parting with more taxpayer money.
Congress’s current immigration debate is long on enforcement, but short on economics.
To make people healthier, he should step back and let other organizations take the lead.
Why don’t people take risks and start new businesses?
Vinod Khosla, a Silicon Valley legend, is leading the venture capital rush into replacements for gasoline: biofuels made from corn and rougher stuff like switchgrass. But if prices fall and political subsidies vanish, the bubble may burst.
A new weekly feature.
Wednesday’s announcement of new U.S. sanctions creates the impression of action—but it probably won’t actually help those who are dying in Sudan.